ADAM17 and neoplasm: Tumour volume was also reduced in tumours derived from ADAM17‐deficient FGFR2‐mutant EC cells (MFE280A17−/−, MFE296A17−/−, AN3CAA17−/−, Figure 7E–H), further corroborating that ADAM17 activity is critical for tumour growth in FGFR2‐mutant EC cells (Figure 7E–H).